You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
美股異動|諾和諾德盤前升1.55% 司美格魯肽在中國獲批用於長期體重管理
格隆匯 06-25 16:11
諾和諾德(NVO.US)美股盤前升1.55%,報144.49美元,開盤後有望衝擊歷史新高。消息面上,從諾和諾德中國方面獲悉,近日,國家藥品監督管理局批准了其研發生產的諾和盈(用於長期體重管理的司美格魯肽注射液)在中國的上市申請。據悉,諾和盈能夠實現平均17%(16.8kg)的體重降幅,併為患者帶來超越減重的多重健康獲益,其安全性得到了廣泛驗證。此外,當地時間週一,諾和諾德在官網宣佈將投資41億美元,在美國北卡羅來納州克萊頓建廠,以增加其重磅減肥藥Wegovy、糖尿病治療藥物Ozempic和其他注射藥物的供應。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account